99 related articles for article (PubMed ID: 32022375)
1. Therapeutic potential of combination therapy of soluble VEGF receptor 1 and conventional chemotherapy for ovarian cancer growth.
Sato N; Kumasawa K; Yamashita M; Miyake T; Nakamura H; Kimura T
J Obstet Gynaecol Res; 2020 Apr; 46(4):636-645. PubMed ID: 32022375
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
3. Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.
Tyulyandina A; Harrison D; Yin W; Stepanova E; Kochenkov D; Solomko E; Peretolchina N; Daeyaert F; Joos JB; Van Aken K; Byakhov M; Gavrilova E; Tjulandin S; Tsimafeyeu I
Invest New Drugs; 2017 Apr; 35(2):127-133. PubMed ID: 27812884
[TBL] [Abstract][Full Text] [Related]
4. Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways.
Jia L; Zhou J; Zhao H; Jin H; Lv M; Zhao N; Zheng Z; Lu Y; Ming Y; Yu Y
Oncol Rep; 2017 Oct; 38(4):2464-2470. PubMed ID: 28791374
[TBL] [Abstract][Full Text] [Related]
5. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
[TBL] [Abstract][Full Text] [Related]
6. Soluble VEGF receptor 1 (sFLT1) induces non-apoptotic death in ovarian and colorectal cancer cells.
Miyake T; Kumasawa K; Sato N; Takiuchi T; Nakamura H; Kimura T
Sci Rep; 2016 Apr; 6():24853. PubMed ID: 27103202
[TBL] [Abstract][Full Text] [Related]
7. Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer.
Liu J; Agopiantz M; Poupon J; Wu Z; Just PA; Borghese B; Ségal-Bendirdjian E; Gauchotte G; Gompel A; Forgez P
Clin Cancer Res; 2017 Nov; 23(21):6516-6528. PubMed ID: 28790113
[No Abstract] [Full Text] [Related]
8. COM33 suppresses carboplatin-induced epithelial-mesenchymal transition via inhibition of Twist1 in ovarian cancer.
Zhou Z; Jin L; Shen J; Shi W; Xu Y; Ye L; Liu J; Pan J
Acta Biochim Biophys Sin (Shanghai); 2022 Dec; 55(1):34-42. PubMed ID: 36647720
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment.
Westfall SD; Skinner MK
Mol Cancer Ther; 2005 Nov; 4(11):1764-71. PubMed ID: 16275998
[TBL] [Abstract][Full Text] [Related]
10. The impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells.
Whitworth JM; Londoño-Joshi AI; Sellers JC; Oliver PJ; Muccio DD; Atigadda VR; Straughn JM; Buchsbaum DJ
Gynecol Oncol; 2012 Apr; 125(1):226-30. PubMed ID: 22155260
[TBL] [Abstract][Full Text] [Related]
11. Low-dose aspirin reduces hypoxia-induced sFlt1 release via the JNK/AP-1 pathway in human trophoblast and endothelial cells.
Lin L; Li G; Zhang W; Wang YL; Yang H
J Cell Physiol; 2019 Aug; 234(10):18928-18941. PubMed ID: 31004367
[TBL] [Abstract][Full Text] [Related]
12. FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.
Kreitzburg KM; Fehling SC; Landen CN; Gamblin TL; Vance RB; Arend RC; Katre AA; Oliver PG; van Waardenburg RCAM; Alvarez RD; Yoon KJ
Cancer Lett; 2018 Nov; 436():75-86. PubMed ID: 30120964
[TBL] [Abstract][Full Text] [Related]
13. The plant extract of Pao pereira potentiates carboplatin effects against ovarian cancer.
Yu J; Chen Q
Pharm Biol; 2014 Jan; 52(1):36-43. PubMed ID: 24033267
[TBL] [Abstract][Full Text] [Related]
14. Anti-Proliferative and Apoptotic Activities of Müllerian Inhibiting Substance Combined with Calcitriol in Ovarian Cancer Cell Lines.
Jung YS; Kim HJ; Seo SK; Choi YS; Nam EJ; Kim S; Kim SW; Han HD; Kim JW; Kim YT
Yonsei Med J; 2016 Jan; 57(1):33-40. PubMed ID: 26632380
[TBL] [Abstract][Full Text] [Related]
15. [Effect of extracellular signal regulated kinase signal pathway on apoptosis induced by MG262 in ovarian cancer cells].
Wang WX; Kong BH; Li P; Song K; Qu X; Cui BX; Jiang J; Zhang YZ; Yang XS
Zhonghua Fu Chan Ke Za Zhi; 2008 Sep; 43(9):690-4. PubMed ID: 19087521
[TBL] [Abstract][Full Text] [Related]
16. Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment.
Weigel MT; Rath K; Alkatout I; Wenners AS; Schem C; Maass N; Jonat W; Mundhenke C
Oncology; 2014; 87(4):232-45. PubMed ID: 25116401
[TBL] [Abstract][Full Text] [Related]
17. Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy.
Wong-Brown MW; van der Westhuizen A; Bowden NA
BMC Cancer; 2022 Jan; 22(1):100. PubMed ID: 35073851
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of cytotoxicity of the taxane and platinum agents combination treatment in a panel of human ovarian carcinoma cell lines.
Smith JA; Ngo H; Martin MC; Wolf JK
Gynecol Oncol; 2005 Jul; 98(1):141-5. PubMed ID: 15963813
[TBL] [Abstract][Full Text] [Related]
19. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
20. The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts.
Mao W; Peters HL; Sutton MN; Orozco AF; Pang L; Yang H; Lu Z; Bast RC
Cancer; 2019 Apr; 125(8):1267-1280. PubMed ID: 30620384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
